Table 2 Treatment-emergent adverse events reported by ≥ 5% of treated patients by preferred term and study drug relationship: data are number of patients with rates in brackets (N = 95)
| Â | All Causalities | Treatment Related |
|---|---|---|
Patients with ≥ 1 adverse event | 75 (78.9) | 55 (57.9) |
Pyrexia | 25 (26.3) | 11 (11.6) |
Asthenia | 13 (13.7) | 9 (9.5) |
Dyspnea | 11 (11.6) | 1 (1.1) |
Neutropenia | 10 (10.5) | 10 (10.5) |
Vomiting | 10 (10.5) | 9 (9.5) |
Diarrhea | 10 (10.5) | 9 (9.5) |
Anemia | 10 (10.5) | 8 (8.4) |
Nausea | 9 (9.5) | 9 (9.5) |
Fatigue | 9 (9.5) | 8 (8.4) |
Cough | 8 (8.4) | 3 (3.2) |
Anorexia | 6 (6.3) | 1 (1.1) |
Leucopenia | 5 (5.3) | 5 (5.3) |
Mucosal inflammation | 5 (5.3) | 5 (5.3) |
Thrombocytopenia | 5 (5.3) | 5 (5.3) |
Rash | 5 (5.3) | 4 (4.2) |
Chest pain | 5 (5.3) | 1 (1.1) |
Peripheral Edema | 5 (5.3) | 1 (1.1) |